Role of 5α-reductase inhibitors in androgen-stimulated skin disorders

Journal of Drugs in Dermatology

Volumn 12, Issue 2, 2013, Pages

  Azzouni, Faris ^a   Zeitouni, Nathalie ^a   Mohler, James ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; ANDROGEN; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; DUTASTERIDE; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; LEUPRORELIN; MINOCYCLINE; PLACEBO; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ACNE VULGARIS; ADD ON THERAPY; ANDROGEN BLOOD LEVEL; ANTIANDROGEN THERAPY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; EJACULATION DISORDER; ETHNIC DIFFERENCE; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPERANDROGENISM; IMPOTENCE; IN VITRO STUDY; LIBIDO DISORDER; LONG TERM CARE; MALE TYPE ALOPECIA; PRECOCIOUS PUBERTY; PROSTATE HYPERTROPHY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

5-ALPHA REDUCTASE INHIBITORS; ACNE VULGARIS; ALOPECIA; ANDROGEN ANTAGONISTS; ANDROGENS; FEMALE; HIRSUTISM; HUMANS; MALE; SKIN; SKIN DISEASES;

EID: 84873332638     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Imperato-McGinley J, Zhu YS. Androgens and male physiology - the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198(1-2):51-59.
2. Russell DW, Wilson JD. Steroid 5alpha-reductase: two genes/two enzymes. Ann Rev Biochem.1994;63:25-61.
3. Aumüller G, Eicheler W, Renneberg H, Adermann K, Vilja P, Forssmann WG. Immunocytochemical evidence for differential subcellular localization of 5α-reductase isoenzymes in human tissues. Acta Anat.1996;156(4):241-252.
4. Godoy A, Kawinski E, Li Y, et al. 5α-reductase 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011;71(10):1033-1046.
5. Cantagrel V, Lefeber DJ, Ng BG, et al. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010;142(2):203-217.
6. Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984;114(6):2100-2106.
7. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974; 186(4170):1213-1215.
8. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alphareductase inhibitors. Steroids. 2010;75(2):109-153.
9. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550-554.
10. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179-2184.
11. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.
12. Yamana K, Labrie F, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited finasteride and dutasteride. Horm Mol Biol Clin Invest. 2010;2(3):293-299.
13. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostate hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388-394.
14. McConnell JD, Bruskewetz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostate hyperplasia. N Engl J Med. 1998;338(9):557-563.
15. Essah PA, Wickham EP 3rd, Nunley JR, Nestler JE. Dermatology of androgenrelated disorders. Clin Dermatol. 2006;24(4):289-298.
16. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8(4):201-219.
17. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(9):4116-4123.
18. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16(4):275-284.
19. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther. 2008;21(5):376-391.
20. Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat. 1942;71:451-480.
21. Patterson MN, McPhaul MJ, Hughes LA. Androgen insensitivity syndrome. Baillieres Clin Endocrinol Metab. 1994;8(2):379-404.
22. Imperato-McGinley J, Gautier T, Cai L, Yee B, Epstein J, Pochi P. The androgen control of sebum production: studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab.1993;76(2):524-528.
23. Camacho- Martínez FM. Hair loss in women. Semin Cutan Med Surg. 28(1):19-32.
24. Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol. 1994;130(3):308-314.
25. Tita P, Spina A, Briguglia G, et al. Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma. J Endocrinol Invest. 1996;19(7):484-487.
26. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22(5):419-428.
27. Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11(8):1295-1304.
28. Lakryc EM, Motta EL, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol. 2003;17(1):57-63.
29. Ciotta L, Cianci A, Calogero AE, et al. Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril. 1995;64(2): 299-306.
30. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85(1):89-94.
31. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol. 1999;141(4):361-367.
32. Unluhizarci K, Ozel D, Tanriverdi F, Karaca Z, Kelestimur F. A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism. J Endocrinol Invest. 2009;32(1):37-40.
33. Erenus M, Yücelten D, Durmuşoǧlu F, Gürbüz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril. 1997;68(6):1000-1003.
34. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrin Metab. 1995;80(1):233-238.
35. Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril. 1999;71(3):445-451.
36. Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola G, D'Addario V. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2000;73(4):718-723.
37. Unlühizarci K K, Everest H, Bayram F, Keleştimur F. Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Fertil Steril. 2002;78(6): 1331-1333.
38. Van Neste D, Fuh V, Sanchez Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804-10.
39. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): threeand 4-year results. J Am Acad Dermatol. 2006;55(1):71-74.
40. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.
41. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49.
42. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol. 2002;12(1):32-37.
43. Arca E, Açikgöz G, Taştan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology. 2004;209(2):117-125.
44. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.
45. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6(1):9-13.
46. Eun H, Kwon O, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled phase III study. J Am Acad Dermatol. 2010;63(2):252-258.
47. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768-776.
48. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142(3):298-302.
49. Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47(5):733-739.
50. Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23(3):142-145.
51. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4(5):637-640.
52. Schwartz JI, Tanaka WK, Wang DZ, et al. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentration in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrin Metab. 1997;82(5):1373-1377.
53. Leyden J, Bergfeld W, Drake L, et al. A systemic type 1 5alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol. 2004;50(3):443-447.
54. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol. 2002;57(2):231-234.